A selective inhibitor targeting the CDK12/CDK13–Cyclin K complex was reported to degrade Cyclin K and release P-TEFb from the inhibitory 7SK snRNP reservoir, reversing HIV-1 latency. The study reported reversal both in cell models and in cells derived from people living with HIV-1. The mechanistic framing links Cyclin K degradation to changes in transcription machinery availability, offering a distinct approach from latency strategies centered on latency-reversing agents that act through other pathways. While these findings are still preclinical, they provide a tangible lead for combined latency programs—particularly in settings where latency reservoirs and transcriptional blocks remain major barriers to cure efforts.